Bionano Genomics Appoints Donna Polizio as Its First Ever Global Head of Market Access
November 10 2022 - 8:00AM
Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it has
appointed Donna Polizio as its global head of market access,
further strengthening its leadership team. The appointment of a
global head of market access reflects Bionano’s focus on advancing
the adoption of optical genome mapping (OGM) and working to meet
market needs.
Ms. Polizio was most recently the vice president of U.S. managed
care and reimbursement at Genomic Health, acquired by Exact
Sciences in 2019. In this role, she managed payor contracting and
reimbursements that helped drive profitability of Genomic Health
prior to its acquisition. Ms. Polizio has also held senior
leadership roles in research and development, applications, sales
and market access in multiple global life science and diagnostic
companies.
In this new position, Ms. Polizio will be responsible for being
the company’s advocate with government and private payors to drive
global reimbursement for OGM-based tests, with a strong focus on
the US market. In addition, Ms. Polizio will lead Bionano’s
government relations efforts in connection with legislation that
impacts Bionano, its products, and the genomics industry
generally.
“I am pleased to welcome Donna to Bionano. We believe her
breadth of experience and track record in the diagnostics industry
make her well-suited to help Bionano continue the progress we have
made toward one of our strategic ELEVATE! pillars, which is to
clear the path for reimbursement of OGM-based tests and to change
medical practice to include OGM in guidelines. Donna has been
involved in obtaining coverage and reimbursement for some of the
most valued diagnostics of the last several decades. All of us on
the senior leadership team are really looking forward to partnering
with Donna as she helps propel us to reach new heights,” commented
Erik Holmlin, PhD, president and chief executive officer of Bionano
Genomics.
About Bionano GenomicsBionano Genomics is a
provider of genome analysis solutions that can enable researchers
and clinicians to reveal answers to challenging questions in
biology and medicine. The Company’s mission is to transform the way
the world sees the genome through OGM solutions, diagnostic
services and software. The Company offers OGM solutions for
applications across basic, translational and clinical research.
Through its Lineagen, Inc. d/b/a Bionano Laboratories business, the
Company also provides diagnostic testing for patients with clinical
presentations consistent with autism spectrum disorder and other
neurodevelopmental disabilities. Through its BioDiscovery business,
the Company also offers an industry-leading, platform-agnostic
software solution, which integrates next-generation sequencing and
microarray data designed to provide analysis, visualization,
interpretation and reporting of copy number variants,
single-nucleotide variants and absence of heterozygosity across the
genome in one consolidated view. For more information, visit
www.bionanogenomics.com, www.bionanolaboratories.com, or
www.biodiscovery.com.
Forward-Looking Statements of Bionano
GenomicsThis press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Words such as “believe” and similar expressions
(as well as other words or expressions referencing future events,
conditions or circumstances) convey uncertainty of future events or
outcomes and are intended to identify these forward-looking
statements. Forward-looking statements include statements regarding
our intentions, beliefs, projections, outlook, analyses or current
expectations concerning, among other things, the ability of
obtaining reimbursement for OGM-based tests. Each of these
forward-looking statements involves risks and uncertainties. Actual
results or developments may differ materially from those projected
or implied in these forward-looking statements. Factors that may
cause such a difference include the risks and uncertainties
associated with: the impact of adverse geopolitical and
macroeconomic events, such as the COVID-19 pandemic and the ongoing
conflict between Ukraine and Russia, on our business and the global
economy; general market conditions; changes in the competitive
landscape and the introduction of competitive technologies or
improvements to existing technologies; failure to obtain
reimbursement for OGM-based tests; changes in our strategic and
commercial plans; our ability to obtain sufficient financing to
fund our strategic plans and commercialization efforts; the ability
of medical and research institutions to obtain funding to support
adoption or continued use of our technologies; and the risks and
uncertainties associated with our business and financial condition
in general, including the risks and uncertainties described in our
filings with the Securities and Exchange Commission, including,
without limitation, our Annual Report on Form 10-K for the year
ended December 31, 2021 and in other filings subsequently made by
us with the Securities and Exchange Commission. All forward-looking
statements contained in this press release speak only as of the
date on which they were made and are based on management’s
assumptions and estimates as of such date. We do not undertake any
obligation to publicly update any forward-looking statements,
whether as a result of the receipt of new information, the
occurrence of future events or otherwise.
CONTACTSCompany Contact:Erik Holmlin,
CEOBionano Genomics, Inc.+1 (858)
888-7610eholmlin@bionanogenomics.com
Investor Relations:Amy ConradJuniper Point+1 (858)
366-3243amy@juniper-point.com
Bionano Genomics (NASDAQ:BNGO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Bionano Genomics (NASDAQ:BNGO)
Historical Stock Chart
From Sep 2023 to Sep 2024